NEW YORK (GenomeWeb) – With its recent acquisition of diagnostics developer Armune BioScience, Exact Sciences is upping its investment in protein biomarkers, which the company sees as potential complements to its DNA methylation markers.

Exact announced the deal during its presentation last week at the JP Morgan Healthcare Conference in San Francisco, though it revealed little beyond the fact of the acquisition.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.